{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:08:11Z","timestamp":1769972891089,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI16C1501"],"award-info":[{"award-number":["HI16C1501"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0488-2","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T08:03:38Z","timestamp":1549267418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The ability of whole-body SUVmax in F-18 FDG PET\/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Gun Oh.","family":"Chong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin Young","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Soo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Gy","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/bjc.2017.35","volume":"116","author":"SJ Kim","year":"2017","unstructured":"Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer. 2017;116:964\u201371.","journal-title":"Br J Cancer"},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329.","journal-title":"N Engl J Med"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","volume":"170","author":"WJ Hoskins","year":"1994","unstructured":"Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248\u201359.","journal-title":"J Clin Oncol"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","volume":"105","author":"JY Hou","year":"2007","unstructured":"Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol. 2007;105:211\u20137.","journal-title":"Gynecol Oncol"},{"key":"488_CR7","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.18632\/oncotarget.23808","volume":"9","author":"M Qin","year":"2017","unstructured":"Qin M, Jin Y, Ma L, Zhang YY, Pan LY. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. Oncotarget. 2017;9:8614\u201328.","journal-title":"Oncotarget"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2014.07.002","volume":"134","author":"RS Suidan","year":"2014","unstructured":"Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014;134:455\u201361.","journal-title":"Gynecol Oncol"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/gyno.2000.5749","volume":"77","author":"DS Chi","year":"2000","unstructured":"Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol. 2000;77:227\u201331.","journal-title":"Gynecol Oncol"},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","volume":"13","author":"A Fagotti","year":"2006","unstructured":"Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13:1156\u201361.","journal-title":"Ann Surg Oncol"},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00261-009-9578-8","volume":"35","author":"L Funicelli","year":"2010","unstructured":"Funicelli L, Travaini LL, Landoni F, Trifir\u00f2 G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET\/CT. Abdom Imaging. 2010;35:701\u20137.","journal-title":"Abdom Imaging"},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/IGC.0b013e3181e82a7f","volume":"20","author":"P Bhosale","year":"2010","unstructured":"Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, et al. Clinical utility of positron emission tomography\/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010;20:936\u201344.","journal-title":"Int J Gynecol Cancer"},{"key":"488_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.1993.11.1.166","volume":"11","author":"BE Nelson","year":"1993","unstructured":"Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993;11:166\u201372.","journal-title":"J Clin Oncol"},{"key":"488_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A","volume":"89","author":"RE Bristow","year":"2000","unstructured":"Bristow RE, Duska LR, Lambrou NC, Fishman EK, O\u2019Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532\u201340.","journal-title":"Cancer"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cncr.20376","volume":"101","author":"SC Dowdy","year":"2004","unstructured":"Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004;101:346\u201352.","journal-title":"Cancer"},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","volume":"139","author":"M Petrillo","year":"2015","unstructured":"Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V, et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol Oncol. 2015;139:5\u20139.","journal-title":"Gynecol Oncol"},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ygyno.2015.03.049","volume":"137","author":"NR G\u00f3mez-Hidalgo","year":"2015","unstructured":"G\u00f3mez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015;137:553\u20138.","journal-title":"Gynecol Oncol"},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000159266","volume":"75","author":"A Fagotti","year":"2008","unstructured":"Fagotti A, Fanfani F, Rossitto C, Lorusso D, De Gaetano AM, Giordano A, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy. Oncology. 2008;75:152\u20138.","journal-title":"Oncology"},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1007\/s00330-015-3729-9","volume":"25","author":"HA Vargas","year":"2015","unstructured":"Vargas HA, Burger IA, Goldman DA, Micc\u00f2 M, Sosa RE, Weber W, et al. Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol. 2015;25:3348\u201353.","journal-title":"Eur Radiol"},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejrad.2017.05.036","volume":"93","author":"R Gallicchio","year":"2017","unstructured":"Gallicchio R, Nardelli A, Venetucci A, Capacchione D, Pelagalli A, Sirignano C, et al. F-18 FDG PET\/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol. 2017;93:107\u201313.","journal-title":"Eur J Radiol"},{"key":"488_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Gynecologic Oncology Group, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124\u201332.","journal-title":"Ann Surg"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0488-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T06:37:18Z","timestamp":1606372638000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0488-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Retrospective data collection and analysis were approved by the Institutional Review Board of Kyungpook National University Chilgok Hospital. The need for informed consent was waived due to the retrospective design of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"12"}}